Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials focused on lung and heart disease, today announced that it has raised $20 million in Series B funding led by Molten Ventures. Existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension also participated in the round. This new capital will support the expansion of the company’s 3D deep learning imaging portfolio, in parallel with commercial expansion to address demand across key emerging treatment markets for lung and heart diseases.
The company is building an AI imaging lab to house Qureight’s 3D thoracic imaging infrastructure model, significantly reducing both data requirements and time needed to develop new disease models. This will enable Qureight to bring new products to market in new disease areas where there is high demand for advanced image analysis to improve clinical trial design, such as asthma, pulmonary hypertension, bronchiectasis, and drug-induced pulmonary toxicity. The new disease model complements Qureight’s existing model in pulmonary fibrosis, expands the company’s market reach, and solidifies its position as a leading imaging company with an end-to-end, regulatory-compliant, disease-independent clinical trial platform. To support this growth and meet the demand for imaging CRO services, this funding will enable Qureight to expand its commercial team and further strengthen its market position.
Additionally, this funding will enable the development of Qureight’s AI-powered quantitative image analysis platform, further improving the speed and design of clinical trials. The Qureight platform includes:
- A global imaging CRO service that improves image processing in clinical trials and supports rapid onboarding and patient participation decisions in the field.
- Proprietary AI lung imaging biomarkers enable quantification of compartment-specific structural changes indicative of disease progression in clinical trials.
- Data science products that include synthetic control arms that enable comparisons with real test arms and reduce the cost and duration of studies.
Qureight’s services are already being used by biopharmaceutical partners to provide real-time insights and accurate endpoints to accelerate clinical trials for many fibrotic lung diseases.
“The global lung and heart clinical trials market is expected to grow to USD 27.5 billion by 2030, at a CAGR of 6.9% over the next six years. We are strategically positioned to address this market with an end-to-end integrated imaging platform for clinical trials.” We are very pleased to welcome Dr. Deakin and would like to thank Hargreave Hale to the Board and our existing investors who participated in this round. Their continued support reflects their confidence in our enterprise-grade imaging platform and world-class team as we meet the critical demands of accelerating clinical trials.” Dr. Muhunthan Thillai, MD PhD, co-founder and CEO of Qureight, commented: “Expanding our 3D imaging deep learning models in our new AI lab complements our existing leadership in pulmonary fibrosis, enables us to enter new markets, and solidifies our leadership position in the lung and cardiac imaging CRO market.”
Qureight demonstrates how AI powered by real-world data can accelerate discovery and transform clinical research. This team’s rapid deployment of solutions in areas of unmet need highlights its unique ability to drive the next generation of medical innovation. We look forward to working with Mfuntan and the team to realize this vision. ”
Dr. Inga Deakin, Partner at Molten Ventures
